Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | TP53 | P04637 | 4/20 | 0.37 |
| ▸ | CCR2 | P41597 | 2/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28731464 | 0.79 | TAAR1 (0.33) | — | |
| SCHEMBL20553759 | 0.79 | TAAR1 (0.33) | — | |
| SCHEMBL23795250 | 0.78 | TP53 (0.52) | SMN1; SMN2TP53CCR2THRBMAPT | |
| SCHEMBL21925726 | 0.78 | APP (0.33) | — | |
| SCHEMBL23795303 | 0.76 | TP53 (0.43) | SMN1; SMN2TP53MDM2THRBMAPT | |
| SCHEMBL7937235 | 0.76 | HTR2A (0.39) | SMN1; SMN2TP53CCR2THRBMAPT | |
| SCHEMBL23795253 | 0.75 | TP53 (0.54) | SMN1; SMN2TP53CCR2THRBMAPT | |
| SCHEMBL21925720 | 0.75 | SMN1; SMN2 (0.38) | SMN1; SMN2TP53CCR2THRBMAPT | |
| SCHEMBL24178022 | 0.68 | FSHR (0.43) | SMN1; SMN2MAPTKMT2A | |
| SCHEMBL15614864 | 0.67 | BACE1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12127473-B2 | Di-, tri- and tetraphenylindane derivates and their use in organic electronics | DOTTIKON ES HOLDING AG (CH) | 2024-10-22 | — | — | US | disclosed |
| US-20220006020-A1 | DI-, TRI- AND TETRAPHENYLINDANE DERIVATES AND THEIR USE IN ORGANIC ELECTRONICS | DOTTIKON ES HOLDING AG (CH) | 2022-01-06 | — | — | US | disclosed |
| EP-3877357-A1 | DI-, TRI- AND TETRAPHENYLINDANE DERIVATIVES AND THEIR USE IN ORGANIC ELECTRONICS | DOTTIKON ES HOLDING AG (CH) | 2021-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220006020-A1 | DI-, TRI- AND TETRAPHENYLINDANE DERIVATES AND THEIR USE IN ORGANIC ELECTRONICS | NR0B2, KCNJ2, TRRAP | SMN1; SMN2 3918/4885TP53 3228/4885CCR2 616/4885 |
| US-12127473-B2 | Di-, tri- and tetraphenylindane derivates and their use in organic electronics | NR0B2, KCNJ2, TRRAP | SMN1; SMN2 3918/4885TP53 3228/4885CCR2 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.